Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Li, Qiong ^a   Zhang, Daoxiang ^b   Chen, Xiaoying ^a   He, Lei ^a   Li, Tianming ^a   Xu, Xiaoping ^a   Li, Min ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MEMBRANE PROTEIN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

CELL LINE; CELL NUCLEUS; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; HT-29 CELL LINE; HUMAN; TRANSCRIPTION INITIATION; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HCT116 CELLS; HEK293 CELLS; HT29 CELLS; HUMANS; MEMBRANE PROTEINS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; THYROID HORMONES; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84946893716     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16082     Document Type: Article

References (32)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin. 61, 69-90 (2011).
2. Wheeler, D. L., Dunn, E. F. & Harari, P. M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 7, 493-507 (2010).
3. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 483, 100-103 (2012).
4. Lou, Y. F. et al. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. Plos One. 9, e97719 (2014).
5. Kijima, T. et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Diffe. 13, 355-362 (2002).
6. Kim, H. S. et al. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, P53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer. 116, 676-685 (2010).
7. Schindler, C. & Darnell, J. J. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annual review of biochemistry. 64, 621-651 (1995).
8. Cao, X., Tay, A., Guy, G. R. & Tan, Y. H. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol. 16, 1595-1603 (1996).
9. Lo, H. W., Cao, X., Zhu, H. & Ali-Osman, F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 14, 6042-6054 (2008).
10. Haura, E. B., Sommers, E., Song, L., Chiappori, A. & Becker, A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol. 5, 1806-1814 (2010).
11. Gao, X., Wang, H., Yang, J. J., Liu, X. & Liu, Z. R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell. 45, 598-609 (2012).
12. Yang, P., Li, Z., Fu, R., Wu, H. & Li, Z. Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. Cell Signal. 26, 1853-1862 (2014).
13. Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452, 230-233 (2008).
14. Dombrauckas, J. D., Santarsiero, B. D. & Mesecar, A. D. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry. 44, 9417-9429 (2005).
15. Mazurek, S., Boschek, C. B., Hugo, F. & Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 15, 300-308 (2005).
16. Hoshino, A., Hirst, J. A. & Fujii, H. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J Biol Chem. 282, 17706-17711 (2007).
17. Stetak, A. et al. Nuclear Translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 67, 1602-1608 (2007).
18. Lee, J., Kim, H. K., Han, Y. M. & Kim, J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol. 40, 1043-1054 (2008).
19. Luo, W. et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 145, 732-744 (2011).
20. Yang, W. et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 480, 118-122 (2011).
21. Yoo, B. C. et al. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer. 108, 532-539 (2004).
22. Guo, W. et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol. 137, 65-72 (2011).
23. Ng, K. & Zhu, A. X. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol. 65, 8-20 (2008).
24. Merla, A. & Goel, S. Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. Chemother Res Pract. 2012, 387172 (2012).
25. Li, C., Iida, M., Dunn, E. F., Ghia, A. J. & Wheeler, D. L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 28, 3801-3813 (2009).
26. Nevo, J. et al. Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance. Clin Cancer Res. 15, 6570-6581 (2009).
27. Darnell, J. E. Validating Stat3 in cancer therapy. Nat Med. 11, 595-596 (2005).
28. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 9, 798-809 (2009).
29. Chen, W. et al. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver Int. 32, 70-77 (2012).
30. Chiu, H. C. et al. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochem Pharmacol. 81, 1263-1270 (2011).
31. Wei, X. Mechanism of EGER-related cancer drug resistance. Anticancer Drugs. 22, 963-970 (2011).
32. Yang, W. et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol. 14, 1295-1304 (2012).